An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate.
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Ibandronic acid (Primary) ; Ibandronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms PRIOR
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 20 Jun 2006 New trial record.